Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CE mark supreme, says UK's ABHI (Association of British Health-Care Industries):

This article was originally published in Clinica

Executive Summary

A new UK quality mark, British Made for Quality (BMfQ), is due to be unveiled next month as part of a new campaign to promote UK-manufactured goods for both the domestic and export markets. For the British medical devices industry, however, the "CE mark is the only mark we need to guarantee safety, quality and performance", Gordon Aylward, director-general of the Association of British Health-Care Industries (ABHI), told Clinica. The ABHI does not encourage the introduction of additional quality marks, he said, adding that there has been "quite a campaign to avoid other marks appearing".

You may also be interested in...



Health And Wellness Trademark Review 3 December, 2019

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

HBW Market News: FTC Ends Another Supplement Scam, Australia Win For ChromaDex, GOED Report, Herbalife

Herbalife opens 9,200 square-foot training facility in China; GOED's latest annual market report, covering 2017-2018, is available; ChromaDex has two-tear exclusivity for nicotinamide riboside chloride in Australia; and A.S. Research arthritis claims for Synovia end in FTC settlement.

Deal Watch: AstraZeneca Continues Divestments By Offloading US/Canada Seroquel Rights

Pharma sells the rights to Germany’s Cheplapharm, which obtained EU/Russia rights in October. Cerecor will acquire Aevi Genomics for $16.1m plus contingent value rights.

Topics

UsernamePublicRestriction

Register

MT064152

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel